EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Individualized treatment and hormonal patterns during administration of human menopausal gonadotropin human chorionic gonadotropin in anovulatory women



Individualized treatment and hormonal patterns during administration of human menopausal gonadotropin human chorionic gonadotropin in anovulatory women



Acta Obstetrica et Gynaecologica Japonica (Japanese Edition) 33(6): 777-785



HMG-HCG [human menopausal gonadotropin-human chorionic gonadotropin] therapy was given to 3 women who had different degrees of an ovulatory disorder. Basal body temperature, cervical mucus and the changes in blood hormones levels were continuously monitored until all 3 women became pregnant. Since much difference was found in the individual ovarian sensitivity to gonadotropin, the ovarian reaction was observed when administering 150 IU HMG every day. When some maturity of ovarian follicles was observed, the dose of HMG was decreased to the level of follicle stimulating hormone in the normal menstrual cycle. Considering the time needed for follicular maturation, HMG was changed to HCG 4 or 5 days after cervical mucus increased to 0.2 ml. or more and showed 2-grade of crystallization. With pituitary anovulatory women, a low dose of HCG together with HMG was administered to accelerate follicular maturation. Clomiphene was used in addition to HMG-HCG to increase ovarian sensitivity to gonadotropin. For severe anovulatory women resisting this treatment (except hypergonadotropin pattern), the relation of cervical mucus and hormones in blood during the treatment cycle must be studied to determine the next treatment.

(PDF emailed within 1 workday: $29.90)

Accession: 005669095

Download citation: RISBibTeXText



Related references

Results of human menopausal gonadotropin humegon human chorionic gonadotropin therapy in 6096 treatment cycles of 2166 japanese women with anovulatory infertility. European Journal of Obstetrics & Gynecology & Reproductive Biology 19(1): 43-52, 1985

Clinical results and endocrinological studies in anovulatory women treated with human menopausal gonadotropin human chorionic gonadotropin. Japanese Journal of Fertility & Sterility 27(1): 12-25, 1982

Serial monitoring of serum estradiol and progesterone levels during the human menopausal gonadotropin human chorionic gonadotropin therapy in 6 anovulatory women. International Journal of Gynecology & Obstetrics 19(1): 53-56, 1981

Anovulatory sterility. Treatment with human menopausal gonadotropin and human chorionic gonadotropin. Ugeskrift for Laeger 146(9): 640-643, 1984

Treatment of anovulatory infertility with human menopausal gonadotropin followed by human chorionic gonadotropin. American Journal of Obstetrics and Gynecology 101(4): 439-447, 1968

The testicular response to human chorionic gonadotropin and human chorionic gonadotropin human menopausal gonadotropin treatment in patients with hypogonadotropic eunuchoidism influence of endogenous fsh. Journal of Steroid Biochemistry 20(6 PART B): 1603, 1984

Induction of ovulation by human menopausal gonadotropin human chorionic gonadotropin during chronic administration of an gonadotropin releasing hormone agonist buserelin. Acta Endocrinologica Supplementum 108(267): 97, 1985

Comparative study of hormonal dynamics in pregnant and nonpregnant cycles during pulsatile subcutaneous administration of human menopausal gonadotropin in anovulatory infertile women. Fertility and Sterility 60(2): 254-261, 1993

Experience with combined individualized method of human menopausal gonadotropin human chorionic gonadotropin therapy. International Journal of Fertility 28(2): 85-90, 1983

Buserelin suppression of endogenous gonadotropin secretion in infertile women with ovarian feedback disorders given human menopausal/human chorionic gonadotropin treatment. Fertility and Sterility 49(3): 399-403, 1988

Serum human chorionic gonadotropin levels are correlated with body mass index rather than route of administration in women undergoing in vitro fertilization-embryo transfer using human menopausal gonadotropin and intracytoplasmic sperm injection. Fertility & Sterility 75(4): 700-704, April, 2001

Trial of support treatment with human chorionic gonadotropin in the luteal phase after treatment with buserelin and human menopausal gonadotropin in women taking part in an in vitro fertilisation program. British Medical Journal 298(6686): 1483-1486, 1989

Preliminary report about a modified gonadotropin (human menopausal gonadotropin/human chorionic gonadotropin) treatment in infertile patients with premature luteinization. Fertility and Sterility 41(5): 714-718, 1984

Buserelin**Hoechst AG, Frankfurt/Main, FRG. suppression of endogenous gonadotropin secretion in infertile women with ovarian feedback disorders given human menopausal/human chorionic gonadotropin treatment. Fertility and Sterility 49(3): 399-403, 1988

Combined human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) treatment in gonadotropin-deficient males with pituitary dwarfism. Acta Paediatrica Japonica 34(2): 243-8; Discussion 249-50, 1992